• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Hutchmed eyes Chinese approval for autoimmune disorder drug after phase 3 success

cafead

Administrator
Staff member
  • cafead   Aug 21, 2023 at 10:42: AM
via Hutchmed is gearing up to submit sovleplenib for approval in the company’s native China after the Syk inhibitor scored a phase 3 win.

article source